We are live on ! Find out more
PHXM

Phaxiam Therapeutics

Delisted

PHXM was delisted on the 8th of March, 2024.

10 hedge funds and large institutions have $101M invested in Phaxiam Therapeutics in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

14.84% more ownership

Funds ownership: 0% → 14.84% (+15%)

Holders
10
Holders Change
+10
Holders Change %
–
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

PHXM Hedge Fund Activity: Q4 2017 in Review

10 of the 4,421 institutional investors tracked by Wall St. Rank reported a position in Phaxiam Therapeutics (PHXM) for Q4 2017, worth a combined $101M.

Buyers outnumbered sellers: 10 funds opened new PHXM positions and 0 closed out — a net gain of 10 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $73M.

  • 10 institutional investors held Phaxiam Therapeutics (PHXM) as of Q4 2017, up from 0 in Q3 2017.
  • Funds reported $101M of Phaxiam Therapeutics stock for Q4 2017.
  • 10 funds opened new Phaxiam Therapeutics positions in Q4 2017 and 0 closed out, a net change of +10 holders.
  • The largest Phaxiam Therapeutics buyer in Q4 2017 was Baker Bros. Advisors, an estimated $73M added.

Based on aggregated 13F filings for Q4 2017.